[
  {
    "title": "力生制药：公司正在加紧氨酚咖匹林、vc等产品的生产",
    "href": "http://stock.jrj.com.cn/2022/12/20101837224752.shtml",
    "datetime": "2022-12-20 10:18:55",
    "code": "002393"
  },
  {
    "title": "力生制药：拟于12月30日召开临时股东大会 审议为子公司提供担保相关提案",
    "href": "http://stock.jrj.com.cn/2022/12/14152337211909.shtml",
    "datetime": "2022-12-14 15:23:49",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：向81名激励对象首次授予153.8万股限制性股票",
    "href": "http://stock.jrj.com.cn/2022/12/09193937202617.shtml",
    "datetime": "2022-12-09 19:39:53",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：甲硝唑片通过一致性评价",
    "href": "http://stock.jrj.com.cn/2022/12/06154737191935.shtml",
    "datetime": "2022-12-06 15:47:00",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：缬沙坦氨氯地平片(Ⅰ)通过上市许可申请",
    "href": "http://stock.jrj.com.cn/2022/11/22154837157440.shtml",
    "datetime": "2022-11-22 15:48:03",
    "code": "002393"
  },
  {
    "title": "力生制药2022年前三季度净利1.13亿同比增长14.86% 收回到期理财产品",
    "href": "http://stock.jrj.com.cn/2022/10/26191237086742.shtml",
    "datetime": "2022-10-26 19:12:03",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：第三季度净利4066.98万元，同比增长11.53%",
    "href": "http://stock.jrj.com.cn/2022/10/26160537085669.shtml",
    "datetime": "2022-10-26 16:05:10",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：董事、董事长徐道情到龄荣退",
    "href": "http://stock.jrj.com.cn/2022/10/19120337066385.shtml",
    "datetime": "2022-10-19 12:03:06",
    "code": "002393"
  },
  {
    "title": "【龙虎榜】力生制药10月10日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/10/10180437044525.shtml",
    "datetime": "2022-10-10 18:04:55",
    "code": "002393"
  },
  {
    "title": "力生制药：叶酸片、氢氯噻嗪片通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2022/09/23155237017145.shtml",
    "datetime": "2022-09-23 15:52:09",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：叶酸片通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2022/09/23154337017130.shtml",
    "datetime": "2022-09-23 15:43:59",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：氢氯噻嗪片通过一致性评价",
    "href": "http://stock.jrj.com.cn/2022/09/23154237017132.shtml",
    "datetime": "2022-09-23 15:42:38",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)拟开展票据池业务 额度不超8000万元",
    "href": "http://stock.jrj.com.cn/2022/09/09115836985689.shtml",
    "datetime": "2022-09-09 11:58:15",
    "code": "002393"
  },
  {
    "title": "天津发展(00882.HK)：力生制药半年度净利7195.39万元 同比增长17.47%",
    "href": "http://stock.jrj.com.cn/2022/08/25064836932672.shtml",
    "datetime": "2022-08-25 06:48:38",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)半年度净利润7195.39万元、同比增长17.47%",
    "href": "http://stock.jrj.com.cn/2022/08/24191236931712.shtml",
    "datetime": "2022-08-24 19:12:46",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：拟挂牌转让生化制药天津空港经济区环河南路9号房地产及部分设备",
    "href": "http://stock.jrj.com.cn/2022/06/30210636772973.shtml",
    "datetime": "2022-06-30 21:06:48",
    "code": "002393"
  },
  {
    "title": "力生制药：盐酸多奈哌齐片通过仿制药一致性评价 有利于提升该药品市场竞争力",
    "href": "http://stock.jrj.com.cn/2022/05/05144136569235.shtml",
    "datetime": "2022-05-05 14:41:03",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：盐酸多奈哌齐片通过一致性评价",
    "href": "http://stock.jrj.com.cn/2022/05/05115436567739.shtml",
    "datetime": "2022-05-05 11:54:38",
    "code": "002393"
  },
  {
    "title": "力生制药2022年第一季度净利4195.4万 较上年同期增长16.36%",
    "href": "http://stock.jrj.com.cn/2022/05/03185036546060.shtml",
    "datetime": "2022-05-03 18:50:40",
    "code": "002393"
  },
  {
    "title": "天津发展(00882.HK)：力生制药一季度净利4195.40万元 同比增长16.36%",
    "href": "http://stock.jrj.com.cn/2022/04/27075036480909.shtml",
    "datetime": "2022-04-27 07:50:44",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)一季度净利润4195.40万元 同比增长16.36%",
    "href": "http://stock.jrj.com.cn/2022/04/26160036475736.shtml",
    "datetime": "2022-04-26 16:00:58",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：复方磺胺甲噁唑片通过一致性评价",
    "href": "http://stock.jrj.com.cn/2022/04/13115136322042.shtml",
    "datetime": "2022-04-13 11:51:02",
    "code": "002393"
  },
  {
    "title": "天津发展(00882.HK)：力生制药2021年度净利升1317.3%至1.22亿元 拟10派3元",
    "href": "http://stock.jrj.com.cn/2022/03/25124935079163.shtml",
    "datetime": "2022-03-25 12:49:11",
    "code": "002393"
  },
  {
    "title": "力生制药2021年净利1.22亿同比增长1317.31% 董事长徐道情薪酬65.1万",
    "href": "http://stock.jrj.com.cn/2022/03/24205134938754.shtml",
    "datetime": "2022-03-24 20:51:54",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：2021年度净利润升1317.31%至1.22亿元 拟10派3元",
    "href": "http://stock.jrj.com.cn/2022/03/24174734911665.shtml",
    "datetime": "2022-03-24 17:47:10",
    "code": "002393"
  },
  {
    "title": "力生制药：入选国企改革“科改示范企业”名单 为天津入选两家企业之一",
    "href": "http://stock.jrj.com.cn/2022/03/23152435114632.shtml",
    "datetime": "2022-03-23 15:24:22",
    "code": "002393"
  },
  {
    "title": "力生制药：入选国企改革“科改示范企业”名单 为天津入选两家企业之一",
    "href": "http://stock.jrj.com.cn/2022/03/23152434866775.shtml",
    "datetime": "2022-03-23 15:24:22",
    "code": "002393"
  },
  {
    "title": "力生制药：入选国企改革“科改示范企业”名单 为天津入选两家企业之一",
    "href": "http://stock.jrj.com.cn/2022/03/23152435105701.shtml",
    "datetime": "2022-03-23 15:24:22",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：2021年中央药业双清合剂营收占公司总营收0.3%",
    "href": "http://stock.jrj.com.cn/2022/03/09165334560646.shtml",
    "datetime": "2022-03-09 16:53:53",
    "code": "002393"
  },
  {
    "title": "力生制药双清合剂营业收入占总营收比例较低",
    "href": "http://stock.jrj.com.cn/2022/03/09165334560504.shtml",
    "datetime": "2022-03-09 16:53:40",
    "code": "002393"
  },
  {
    "title": "从“增收不增利”到“增利不增收” 力生制药难靠“降费”推动业绩增长",
    "href": "http://stock.jrj.com.cn/2022/01/24075534200067.shtml",
    "datetime": "2022-01-24 07:55:00",
    "code": "002393"
  },
  {
    "title": "天津发展(00882.HK)：力生制药2021年度净利预增1176.80%-1525.02%",
    "href": "http://stock.jrj.com.cn/2022/01/23200334194795.shtml",
    "datetime": "2022-01-23 20:03:17",
    "code": "002393"
  },
  {
    "title": "力生制药2021年预计净利1.1亿-1.4亿增长1176.8%-1525% 资金利息收益较上年增加",
    "href": "http://stock.jrj.com.cn/2022/01/21191234183818.shtml",
    "datetime": "2022-01-21 19:12:09",
    "code": "002393"
  },
  {
    "title": "力生制药：强化预算管理和成本控制 2021年净利预盈1.1亿至1.4亿元",
    "href": "http://stock.jrj.com.cn/2022/01/21175334183714.shtml",
    "datetime": "2022-01-21 17:53:24",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)2021年度净利润预增1176.80%-1525.02%",
    "href": "http://stock.jrj.com.cn/2022/01/21170534183093.shtml",
    "datetime": "2022-01-21 17:05:31",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：子公司头孢地尼分散片通过一致性评价",
    "href": "http://stock.jrj.com.cn/2021/11/05155233816939.shtml",
    "datetime": "2021-11-05 15:52:31",
    "code": "002393"
  },
  {
    "title": "天津发展(00882.HK)：力生制药前三季净利9771.7万 同比增长23.4%",
    "href": "http://stock.jrj.com.cn/2021/10/25064533744317.shtml",
    "datetime": "2021-10-25 06:45:30",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)第三季度净利润3646.42万元 同比增长61.33%",
    "href": "http://stock.jrj.com.cn/2021/10/22162033733373.shtml",
    "datetime": "2021-10-22 16:20:56",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：上半年净利增8.28%至6125.28万元",
    "href": "http://stock.jrj.com.cn/2021/08/23211033305144.shtml",
    "datetime": "2021-08-23 21:10:17",
    "code": "002393"
  },
  {
    "title": "力生制药2021年半年度净利6125.28万元 同比净利增加8.28%",
    "href": "http://stock.jrj.com.cn/2021/08/23200433304699.shtml",
    "datetime": "2021-08-23 20:04:30",
    "code": "002393"
  },
  {
    "title": "力生制药：我公司尚未与有济医药建立合作关系",
    "href": "http://stock.jrj.com.cn/2021/06/25135232995679.shtml",
    "datetime": "2021-06-25 13:52:32",
    "code": "002393"
  },
  {
    "title": "力生制药：截至目前公司尚无改制计划",
    "href": "http://stock.jrj.com.cn/2021/06/25134932995649.shtml",
    "datetime": "2021-06-25 13:49:29",
    "code": "002393"
  },
  {
    "title": "力生制药：公司目前理财产品余额为7000万元",
    "href": "http://stock.jrj.com.cn/2021/06/25134832995652.shtml",
    "datetime": "2021-06-25 13:48:37",
    "code": "002393"
  },
  {
    "title": "力生制药：设备正在进行安装调试",
    "href": "http://stock.jrj.com.cn/2021/06/25132732995538.shtml",
    "datetime": "2021-06-25 13:27:26",
    "code": "002393"
  },
  {
    "title": "力生制药：公司生产的绝大多数原料药是自用 未有投入市场",
    "href": "http://stock.jrj.com.cn/2021/06/18083632952234.shtml",
    "datetime": "2021-06-18 08:36:04",
    "code": "002393"
  },
  {
    "title": "力生制药：子公司中央药业生产的人参口服液与往年相比销售情况相对稳定",
    "href": "http://stock.jrj.com.cn/2021/06/18083432952233.shtml",
    "datetime": "2021-06-18 08:34:51",
    "code": "002393"
  },
  {
    "title": "力生制药：公司目前生产双清合剂",
    "href": "http://stock.jrj.com.cn/2021/06/18083432952231.shtml",
    "datetime": "2021-06-18 08:34:44",
    "code": "002393"
  },
  {
    "title": "力生制药：公司生产经营均按照计划有序进行",
    "href": "http://stock.jrj.com.cn/2021/06/18083432952223.shtml",
    "datetime": "2021-06-18 08:34:13",
    "code": "002393"
  },
  {
    "title": "力生制药：公司官网持续更新中",
    "href": "http://stock.jrj.com.cn/2021/06/18082532952204.shtml",
    "datetime": "2021-06-18 08:25:04",
    "code": "002393"
  },
  {
    "title": "力生制药：2020年度权益分派实施 每10股派发现金红利1.0元（含税）",
    "href": "http://stock.jrj.com.cn/2021/06/02170932864172.shtml",
    "datetime": "2021-06-02 17:09:12",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)2020年度权益分派10派1元 股权登记日为6月10日",
    "href": "http://stock.jrj.com.cn/2021/06/02164832863651.shtml",
    "datetime": "2021-06-02 16:48:19",
    "code": "002393"
  },
  {
    "title": "力生制药：公司目前尚无继续布局疫苗方面的计划",
    "href": "http://stock.jrj.com.cn/2021/05/27130832828838.shtml",
    "datetime": "2021-05-27 13:08:20",
    "code": "002393"
  },
  {
    "title": "力生制药：公司未来发展主要集中于老慢病领域并完善公司产业链条",
    "href": "http://stock.jrj.com.cn/2021/05/27130332828826.shtml",
    "datetime": "2021-05-27 13:03:49",
    "code": "002393"
  },
  {
    "title": "力生制药：公司维生素C片生产销售一切正常",
    "href": "http://stock.jrj.com.cn/2021/05/27114632828533.shtml",
    "datetime": "2021-05-27 11:46:07",
    "code": "002393"
  },
  {
    "title": "力生制药：天津市北辰区友好综合加工厂原主要是生产来苏水等产品",
    "href": "http://stock.jrj.com.cn/2021/05/12091332740071.shtml",
    "datetime": "2021-05-12 09:13:15",
    "code": "002393"
  },
  {
    "title": "力生制药：公司目前管理层为董事会聘任",
    "href": "http://stock.jrj.com.cn/2021/05/10134132728601.shtml",
    "datetime": "2021-05-10 13:41:37",
    "code": "002393"
  },
  {
    "title": "力生制药：公司目前与药物研究院有限公司有部分合作",
    "href": "http://stock.jrj.com.cn/2021/05/10134032728582.shtml",
    "datetime": "2021-05-10 13:40:00",
    "code": "002393"
  },
  {
    "title": "力生制药：公司目前生产经营一切正常",
    "href": "http://stock.jrj.com.cn/2021/05/10133832728570.shtml",
    "datetime": "2021-05-10 13:38:35",
    "code": "002393"
  },
  {
    "title": "力生制药：母公司目前员工1000人左右",
    "href": "http://stock.jrj.com.cn/2021/05/10130732728383.shtml",
    "datetime": "2021-05-10 13:07:08",
    "code": "002393"
  },
  {
    "title": "力生制药：公司具有原料、制剂一体化的完整产业链",
    "href": "http://stock.jrj.com.cn/2021/05/10123332728189.shtml",
    "datetime": "2021-05-10 12:33:30",
    "code": "002393"
  },
  {
    "title": "力生制药：目前公司原料来源比较稳定",
    "href": "http://stock.jrj.com.cn/2021/05/10122432728147.shtml",
    "datetime": "2021-05-10 12:24:15",
    "code": "002393"
  },
  {
    "title": "力生制药：津联控股无偿划转至泰达控股有利于做优做强国有资本",
    "href": "http://stock.jrj.com.cn/2021/04/30141332486748.shtml",
    "datetime": "2021-04-30 14:13:13",
    "code": "002393"
  },
  {
    "title": "天津发展(00882.HK)：力生制药一季度净利升5.26%至3605.45万元",
    "href": "http://stock.jrj.com.cn/2021/04/28130332470880.shtml",
    "datetime": "2021-04-28 13:03:17",
    "code": "002393"
  },
  {
    "title": "力生制药：公司目前与津沪深生物医药科技有限公司尚无合作",
    "href": "http://stock.jrj.com.cn/2021/04/21090632414302.shtml",
    "datetime": "2021-04-21 09:06:07",
    "code": "002393"
  },
  {
    "title": "力生制药：公司为了保证原料加制剂的产业链完整 建立原料药基地",
    "href": "http://stock.jrj.com.cn/2021/04/21084532414160.shtml",
    "datetime": "2021-04-21 08:45:59",
    "code": "002393"
  },
  {
    "title": "力生制药：公司目前与天药股份的委托生产合同正在履行中",
    "href": "http://stock.jrj.com.cn/2021/04/21084432414143.shtml",
    "datetime": "2021-04-21 08:44:37",
    "code": "002393"
  },
  {
    "title": "力生制药：公司目前尚无产权转让、增资扩股等计划",
    "href": "http://stock.jrj.com.cn/2021/04/21083032414080.shtml",
    "datetime": "2021-04-21 08:30:12",
    "code": "002393"
  },
  {
    "title": "力生制药：公司全资子公司的该产品目前生产和销售情况平稳",
    "href": "http://stock.jrj.com.cn/2021/04/21082832414074.shtml",
    "datetime": "2021-04-21 08:28:41",
    "code": "002393"
  },
  {
    "title": "力生制药：公司目前与药物研究院有限公司有部分合作",
    "href": "http://stock.jrj.com.cn/2021/04/21082632414065.shtml",
    "datetime": "2021-04-21 08:26:09",
    "code": "002393"
  },
  {
    "title": "力生制药：公司持有天津田边制药有限公司24.65%股权",
    "href": "http://stock.jrj.com.cn/2021/04/21081132414030.shtml",
    "datetime": "2021-04-21 08:11:11",
    "code": "002393"
  },
  {
    "title": "力生制药：公司持续推行了各项机制改革 包括职业经理人等多种形式",
    "href": "http://stock.jrj.com.cn/2021/04/21080732414022.shtml",
    "datetime": "2021-04-21 08:07:55",
    "code": "002393"
  },
  {
    "title": "力生制药:公司研发尚未涉及防核功效的药品领域",
    "href": "http://stock.jrj.com.cn/2021/04/15181632380812.shtml",
    "datetime": "2021-04-15 18:16:48",
    "code": "002393"
  },
  {
    "title": "力生制药：公司及其全资子公司拥有品种涉及15大类243个药品批准文号",
    "href": "http://stock.jrj.com.cn/2021/04/15132332378830.shtml",
    "datetime": "2021-04-15 13:23:56",
    "code": "002393"
  },
  {
    "title": "力生制药：公司在人员、财务、机构、业务及资产等方面均独立于控股股东",
    "href": "http://stock.jrj.com.cn/2021/04/15105632378072.shtml",
    "datetime": "2021-04-15 10:56:13",
    "code": "002393"
  },
  {
    "title": "力生制药：河北沧州的原料药基地建设正在紧张有序开展",
    "href": "http://stock.jrj.com.cn/2021/04/15104732378020.shtml",
    "datetime": "2021-04-15 10:47:40",
    "code": "002393"
  },
  {
    "title": "力生制药：公司目前尚未考虑转让持有天津乐敦中药有限公司的股权",
    "href": "http://stock.jrj.com.cn/2021/04/15104632378005.shtml",
    "datetime": "2021-04-15 10:46:16",
    "code": "002393"
  },
  {
    "title": "力生制药：定向增发引进战略投资方进入方案暂时尚未纳入公司本年计划",
    "href": "http://stock.jrj.com.cn/2021/04/15104632378006.shtml",
    "datetime": "2021-04-15 10:46:08",
    "code": "002393"
  },
  {
    "title": "力生制药净利下滑超九成：隐忧丛生 高端领域转型未来存疑",
    "href": "http://stock.jrj.com.cn/2021/03/30110732246870.shtml",
    "datetime": "2021-03-30 11:07:00",
    "code": "002393"
  },
  {
    "title": "力生制药2020年净利861.53万下滑95.42%针剂销售业绩下滑 董事长徐道情薪酬26万",
    "href": "http://stock.jrj.com.cn/2021/03/24182132209894.shtml",
    "datetime": "2021-03-24 18:21:08",
    "code": "002393"
  },
  {
    "title": "天津发展(00882.HK)：力生制药2020年净利降95.42%至861.53万元 拟10派1元",
    "href": "http://stock.jrj.com.cn/2021/03/24130732207767.shtml",
    "datetime": "2021-03-24 13:07:37",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)2020年度净利润降95.42%至861.53万元 拟10派1元",
    "href": "http://stock.jrj.com.cn/2021/03/23204532203934.shtml",
    "datetime": "2021-03-23 20:45:17",
    "code": "002393"
  },
  {
    "title": "力生制药：沧州原料基地建设正在紧张有序推进中",
    "href": "http://stock.jrj.com.cn/2021/03/02103532055888.shtml",
    "datetime": "2021-03-02 10:35:05",
    "code": "002393"
  },
  {
    "title": "力生制药：疫情和带量采购导致公司收入下降",
    "href": "http://stock.jrj.com.cn/2021/03/02103432055878.shtml",
    "datetime": "2021-03-02 10:34:21",
    "code": "002393"
  },
  {
    "title": "力生制药2020年度净利946.81万下滑94.97% 药品价格下降",
    "href": "http://stock.jrj.com.cn/2021/02/25205532027841.shtml",
    "datetime": "2021-02-25 20:55:33",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)业绩快报：2020年度净利润降94.97%至946.81万元",
    "href": "http://stock.jrj.com.cn/2021/02/25172432026301.shtml",
    "datetime": "2021-02-25 17:24:57",
    "code": "002393"
  },
  {
    "title": "力生制药：公司将继续加大科研资金投入",
    "href": "http://stock.jrj.com.cn/2021/02/22130132005181.shtml",
    "datetime": "2021-02-22 13:01:51",
    "code": "002393"
  },
  {
    "title": "力生制药：根据初步估计 本年将对相关资产计提减值准备约6000万元",
    "href": "http://stock.jrj.com.cn/2021/02/22092632004759.shtml",
    "datetime": "2021-02-22 09:26:28",
    "code": "002393"
  },
  {
    "title": "力生制药：公司坚定聚焦主业高质量创新升级的发展道路",
    "href": "http://stock.jrj.com.cn/2021/02/04150731848605.shtml",
    "datetime": "2021-02-04 15:07:27",
    "code": "002393"
  },
  {
    "title": "力生制药：公司将加强对研发平台的建设 围绕心脑血管为主的老慢病领域市场需求 布局产业链相关产品",
    "href": "http://stock.jrj.com.cn/2021/02/04150731848600.shtml",
    "datetime": "2021-02-04 15:07:16",
    "code": "002393"
  },
  {
    "title": "力生制药终止耗时10年项目遭问询 净利预测最高下滑100%的背后",
    "href": "http://stock.jrj.com.cn/2021/02/02073031834286.shtml",
    "datetime": "2021-02-02 07:30:49",
    "code": "002393"
  },
  {
    "title": "力生制药：公司将通过自研、合作开发、并购等形式获得更多的产品",
    "href": "http://stock.jrj.com.cn/2021/02/01131631828927.shtml",
    "datetime": "2021-02-01 13:16:30",
    "code": "002393"
  },
  {
    "title": "力生制药：公司核心产品主要有寿比山牌吲达帕胺片等",
    "href": "http://stock.jrj.com.cn/2021/01/22130131743951.shtml",
    "datetime": "2021-01-22 13:01:29",
    "code": "002393"
  },
  {
    "title": "力生制药：公司与凯莱英的合作主要集中于研发领域",
    "href": "http://stock.jrj.com.cn/2021/01/22102431743238.shtml",
    "datetime": "2021-01-22 10:24:13",
    "code": "002393"
  },
  {
    "title": "力生制药：公司聚焦心脑血管为主的老慢病领域 开展新品筛选 充实了公司产品线",
    "href": "http://stock.jrj.com.cn/2021/01/14085631688642.shtml",
    "datetime": "2021-01-14 08:56:08",
    "code": "002393"
  },
  {
    "title": "力生制药：公司每年的财务报告均经过会计师事务所审计 不存在虚假记载、误导性称述或重大遗漏",
    "href": "http://stock.jrj.com.cn/2021/01/06111831640243.shtml",
    "datetime": "2021-01-06 11:18:08",
    "code": "002393"
  },
  {
    "title": "力生制药2020年预计净利0万-7525万下降60%-100% 药品价格下降",
    "href": "http://stock.jrj.com.cn/2020/12/30203031606701.shtml",
    "datetime": "2020-12-30 20:30:32",
    "code": "002393"
  },
  {
    "title": "【龙虎榜】力生制药12月30日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2020/12/30180531605784.shtml",
    "datetime": "2020-12-30 18:05:10",
    "code": "002393"
  },
  {
    "title": "A股异动 | 力生制药(002393.SZ)跌近9%创逾2年新低 年度纯利同比预降60%-100%",
    "href": "http://stock.jrj.com.cn/2020/12/30135231604278.shtml",
    "datetime": "2020-12-30 13:52:28",
    "code": "002393"
  },
  {
    "title": "力生制药：2020年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/12/29213031597581.shtml",
    "datetime": "2020-12-29 21:30:00",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)2020年度净利润预降60%-100%",
    "href": "http://stock.jrj.com.cn/2020/12/29202531597258.shtml",
    "datetime": "2020-12-29 20:25:45",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：拟终止原超募资金投资项目“23价肺炎球菌多糖疫苗项目”",
    "href": "http://stock.jrj.com.cn/2020/12/29202331597256.shtml",
    "datetime": "2020-12-29 20:23:33",
    "code": "002393"
  },
  {
    "title": "力生制药：力生制药面临前所未有的挑战",
    "href": "http://stock.jrj.com.cn/2020/11/30121331375066.shtml",
    "datetime": "2020-11-30 12:13:43",
    "code": "002393"
  },
  {
    "title": "力生制药2020年前三季度净利7916.92万下滑41.25% 投资收益减少",
    "href": "http://stock.jrj.com.cn/2020/10/26180831134830.shtml",
    "datetime": "2020-10-26 18:08:42",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：前三季度净利降41.25%至7916.92万元",
    "href": "http://stock.jrj.com.cn/2020/10/26161631134246.shtml",
    "datetime": "2020-10-26 16:16:48",
    "code": "002393"
  },
  {
    "title": "力生制药(002393.SZ)：原发性高血压药吲达帕胺片通过一致性评价",
    "href": "http://stock.jrj.com.cn/2020/10/12115931031317.shtml",
    "datetime": "2020-10-12 11:59:34",
    "code": "002393"
  },
  {
    "title": "力生制药2020年上半年净利5656.70万减少36% 部分原材料采购成本上升较大",
    "href": "http://stock.jrj.com.cn/2020/08/24120030574401.shtml",
    "datetime": "2020-08-24 12:00:32",
    "code": "002393"
  },
  {
    "title": "力生制药董事长齐铁栓辞职",
    "href": "http://stock.jrj.com.cn/2020/06/11201529901542.shtml",
    "datetime": "2020-06-11 20:15:00",
    "code": "002393"
  },
  {
    "title": "力生制药：碳酸氢钠片通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2020/05/06121629597933.shtml",
    "datetime": "2020-05-06 12:16:08",
    "code": "002393"
  },
  {
    "title": "力生制药第一季度盈利3425.25万同比下滑22.9% 药品价格下降",
    "href": "http://stock.jrj.com.cn/2020/05/01182329440757.shtml",
    "datetime": "2020-05-01 18:23:18",
    "code": "002393"
  },
  {
    "title": "力生制药：2019年净利润1.88亿元",
    "href": "http://stock.jrj.com.cn/2020/04/23110929356969.shtml",
    "datetime": "2020-04-23 11:09:00",
    "code": "002393"
  },
  {
    "title": "力生制药全资子公司拟对昆仑制药原料药项目追加投资1.11亿元",
    "href": "http://stock.jrj.com.cn/2020/04/10212129259705.shtml",
    "datetime": "2020-04-10 21:21:02",
    "code": "002393"
  },
  {
    "title": "力生制药：中央药业拟约2.45亿元增资其子公司昆仑制药 有利于其长远发展",
    "href": "http://stock.jrj.com.cn/2020/04/10174329258186.shtml",
    "datetime": "2020-04-10 17:43:09",
    "code": "002393"
  },
  {
    "title": "力生制药2019年净利1.87亿元增长1% 销售规模扩大",
    "href": "http://stock.jrj.com.cn/2020/02/28165928915411.shtml",
    "datetime": "2020-02-28 16:59:24",
    "code": "002393"
  },
  {
    "title": "力生制药2019年净利1.87亿增长1% 销售规模扩大",
    "href": "http://stock.jrj.com.cn/2020/02/28164728915316.shtml",
    "datetime": "2020-02-28 16:47:47",
    "code": "002393"
  },
  {
    "title": "力生制药：盐酸异丙嗪片通过仿制药一致性评价 有利于提升该药品市场竞争力",
    "href": "http://stock.jrj.com.cn/2020/01/20134128705475.shtml",
    "datetime": "2020-01-20 13:41:23",
    "code": "002393"
  },
  {
    "title": "力生制药：子公司地块资产将被收储 预计获补偿1.05亿元",
    "href": "http://stock.jrj.com.cn/2020/01/07213228639083.shtml",
    "datetime": "2020-01-07 21:32:03",
    "code": "002393"
  },
  {
    "title": "力生制药：子公司使用土地将被收储 预计获补偿1.05亿元",
    "href": "http://stock.jrj.com.cn/2020/01/07204628638944.shtml",
    "datetime": "2020-01-07 20:46:00",
    "code": "002393"
  },
  {
    "title": "力生制药：间接控股股东国有股权无偿划转",
    "href": "http://stock.jrj.com.cn/2019/10/31190528334741.shtml",
    "datetime": "2019-10-31 19:05:21",
    "code": "002393"
  },
  {
    "title": "力生制药间接控股股东国有股权无偿划转",
    "href": "http://stock.jrj.com.cn/2019/10/31181228334546.shtml",
    "datetime": "2019-10-31 18:12:35",
    "code": "002393"
  },
  {
    "title": "力生制药：落实国企混改 间接控股股东国有股权无偿划转",
    "href": "http://stock.jrj.com.cn/2019/10/31173228334376.shtml",
    "datetime": "2019-10-31 17:32:00",
    "code": "002393"
  },
  {
    "title": "力生制药第三季度盈利4591万 同比增长26.96%",
    "href": "http://stock.jrj.com.cn/2019/10/25085128298212.shtml",
    "datetime": "2019-10-25 08:51:35",
    "code": "002393"
  },
  {
    "title": "力生制药：带量采购政策将对医药行业产生颠覆性的影响",
    "href": "http://stock.jrj.com.cn/2019/09/27155428191672.shtml",
    "datetime": "2019-09-27 15:54:00",
    "code": "002393"
  },
  {
    "title": "力生制药2019年上半年净利8886万 加大原料供应商备案力度",
    "href": "http://stock.jrj.com.cn/2019/08/23075928020719.shtml",
    "datetime": "2019-08-23 07:59:35",
    "code": "002393"
  },
  {
    "title": "力生制药：转让天津新内田制药有限公司30％股权",
    "href": "http://stock.jrj.com.cn/2019/05/31215427649345.shtml",
    "datetime": "2019-05-31 21:54:22",
    "code": "002393"
  },
  {
    "title": "力生制药：拟不低于1018.07万元挂牌转让天津新内田30%股权",
    "href": "http://stock.jrj.com.cn/2019/05/31164027647531.shtml",
    "datetime": "2019-05-31 16:40:48",
    "code": "002393"
  },
  {
    "title": "力生制药：拟转让天津新内田30%股权",
    "href": "http://stock.jrj.com.cn/2019/05/31162027647351.shtml",
    "datetime": "2019-05-31 16:20:46",
    "code": "002393"
  },
  {
    "title": "力生制药2019年第一季度净利4443万元 董事长齐铁栓未持有公司股份",
    "href": "http://stock.jrj.com.cn/2019/04/24154827474715.shtml",
    "datetime": "2019-04-24 15:48:10",
    "code": "002393"
  },
  {
    "title": "力生制药去年净利1.85亿元 同比增长58% 董事长齐铁栓年薪为98万元",
    "href": "http://stock.jrj.com.cn/2019/03/26081927238013.shtml",
    "datetime": "2019-03-26 08:19:45",
    "code": "002393"
  },
  {
    "title": "力生制药：2018年度实现净利润1.84亿元",
    "href": "http://stock.jrj.com.cn/2019/03/24173227218743.shtml",
    "datetime": "2019-03-24 17:32:11",
    "code": "002393"
  },
  {
    "title": "力生制药：2018年年度业绩报告预告(修正公告)",
    "href": "http://stock.jrj.com.cn/2019/01/25201026982046.shtml",
    "datetime": "2019-01-25 20:10:00",
    "code": "002393"
  },
  {
    "title": "力生制药：2018年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/10/24182025254903.shtml",
    "datetime": "2018-10-24 18:20:00",
    "code": "002393"
  },
  {
    "title": "力生制药：间接控股股东天津市医药集团拟进行混改",
    "href": "http://stock.jrj.com.cn/2018/10/09162025177392.shtml",
    "datetime": "2018-10-09 16:20:00",
    "code": "002393"
  },
  {
    "title": "力生制药：2018年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/08/23223024993403.shtml",
    "datetime": "2018-08-23 22:30:00",
    "code": "002393"
  },
  {
    "title": "力生制药：疫苗项目正在稳步推进",
    "href": "http://stock.jrj.com.cn/2018/07/26091024865215.shtml",
    "datetime": "2018-07-26 09:10:00",
    "code": "002393"
  },
  {
    "title": "[仟源医药] 海力生制药 “开工投产仪式”隆重举行",
    "href": "http://stock.jrj.com.cn/2018/04/28000025289252.shtml",
    "datetime": "2018-04-28 00:00:00",
    "code": "002393"
  },
  {
    "title": "力生制药：全资子公司生化制药生产设备更新升级",
    "href": "http://stock.jrj.com.cn/hotstock/2018/04/27075924461889.shtml",
    "datetime": "2018-04-27 07:59:54",
    "code": "002393"
  },
  {
    "title": "力生制药：拟对全资子公司生化制药增资3000万元",
    "href": "http://stock.jrj.com.cn/hotstock/2018/04/27075924461879.shtml",
    "datetime": "2018-04-27 07:59:54",
    "code": "002393"
  },
  {
    "title": "[仟源医药] 海力生制药迎来厂区乔迁之喜",
    "href": "http://stock.jrj.com.cn/2018/01/28000024428892.shtml",
    "datetime": "2018-01-28 00:00:00",
    "code": "002393"
  },
  {
    "title": "力生制药拟终止子公司吸并及新版GMP升级改造项目",
    "href": "http://stock.jrj.com.cn/2017/03/16172422186568.shtml",
    "datetime": "2017-03-16 17:24:05",
    "code": "002393"
  },
  {
    "title": "力生制药：拟转让芥园西道房地产及其附属设施",
    "href": "http://stock.jrj.com.cn/2016/09/13115721453099.shtml",
    "datetime": "2016-09-13 11:57:15",
    "code": "002393"
  },
  {
    "title": "[互动]力生制药已连续六年实施现金分红方案",
    "href": "http://stock.jrj.com.cn/2016/03/28151520748658.shtml",
    "datetime": "2016-03-28 15:15:51",
    "code": "002393"
  },
  {
    "title": "力生制药将不获注津康制药 因其连年亏损",
    "href": "http://stock.jrj.com.cn/2014/02/10202516636744.shtml",
    "datetime": "2014-02-10 20:25:00",
    "code": "002393"
  },
  {
    "title": "力生制药遭股东减持180万股",
    "href": "http://stock.jrj.com.cn/2013/08/15211115692133.shtml",
    "datetime": "2013-08-15 21:11:05",
    "code": "002393"
  },
  {
    "title": "两市中期业绩下降公司汇总：力生制药净利降22%",
    "href": "http://stock.jrj.com.cn/2012/07/24064213892120.shtml",
    "datetime": "2012-07-24 06:42:45",
    "code": "002393"
  },
  {
    "title": "7月23日两市中期业绩下降公司汇总：力生制药净利降22%",
    "href": "http://stock.jrj.com.cn/2012/07/23155713886971.shtml",
    "datetime": "2012-07-23 15:57:00",
    "code": "002393"
  },
  {
    "title": "力生制药拟10派9元 28日股权登记",
    "href": "http://stock.jrj.com.cn/2012/06/24194813569883.shtml",
    "datetime": "2012-06-24 19:48:06",
    "code": "002393"
  },
  {
    "title": "力生制药:购中央药业等以做强化学制药板块",
    "href": "http://stock.jrj.com.cn/2012/05/03171712986749.shtml",
    "datetime": "2012-05-03 17:17:58",
    "code": "002393"
  },
  {
    "title": "力生制药大宗交易数据一览(4/18)",
    "href": "http://stock.jrj.com.cn/hotstock/2012/04/18200412819996.shtml",
    "datetime": "2012-04-18 20:04:47",
    "code": "002393"
  },
  {
    "title": "力生制药整合梦碎 天药意在何为？",
    "href": "http://stock.jrj.com.cn/2012/01/01130011955569.shtml",
    "datetime": "2012-01-01 13:00:25",
    "code": "002393"
  },
  {
    "title": "天药集团整合化学药板块 力生制药收编中央药业",
    "href": "http://stock.jrj.com.cn/2011/11/08034311507093.shtml",
    "datetime": "2011-11-08 03:43:56",
    "code": "002393"
  },
  {
    "title": "力生制药：降压为主的普药龙头企业",
    "href": "http://stock.jrj.com.cn/sme/2010/04/2304187344101.shtml",
    "datetime": "2010-04-23 04:18:31",
    "code": "002393"
  },
  {
    "title": "北京利尔、力生制药公布中签率",
    "href": "http://stock.jrj.com.cn/ipo/2010/04/1421287294410.shtml",
    "datetime": "2010-04-14 21:28:20",
    "code": "002393"
  },
  {
    "title": "北京利尔力生制药今天发行",
    "href": "http://stock.jrj.com.cn/ipo/2010/04/1307037281604.shtml",
    "datetime": "2010-04-13 07:03:44",
    "code": "002393"
  },
  {
    "title": "力生制药：制剂与原料药双轮驱动促发展",
    "href": "http://stock.jrj.com.cn/2010/04/0808287257565.shtml",
    "datetime": "2010-04-08 08:28:14",
    "code": "002393"
  }
]